Analyst Rating Update on Novo Nordisk A/S (NVO)

Novo Nordisk A/S (NYSE:NVO) : Zacks Investment Research ranks Novo Nordisk A/S (NYSE:NVO) as 3, which is a Hold recommendation. 1 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 2 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 3 research analysts is 2.33, which indicates as a Buy.

For this week, the average consensus of the company shares are rated as a Strong Buy.

Novo Nordisk A/S (NYSE:NVO): stock turned positive on Tuesday. Though the stock opened at $51.91, the bulls momentum made the stock top out at $52.25 level for the day. The stock recorded a low of $51.6 and closed the trading day at $52.23, in the green by 2.59%. The total traded volume for the day was 955,734. The stock had closed at $50.91 in the previous days trading.

Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It has a range of diabetes product portfolio, including a portfolio of modern insulins as well as a human once-daily GLP-1 analog. It operates in two segments: diabetes care and biopharmaceuticals. The Companys diabetes care segment covers insulins, GLP-1, other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. Its biopharmaceuticals segment covers the therapy areas of haemophilia care, growth hormone therapy and hormone replacement therapy. The primary production facilities owned by the Company are located at a number of sites in Denmark, and internationally in the United States, France, China and Brazil.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.